NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

先進抗體(2020年):Frost Radar

Frost Radar: Advanced Antibodies, 2020

出版商 Frost & Sullivan 商品編碼 982324
出版日期 內容資訊 英文 33 Pages
商品交期: 最快1-2個工作天內
價格
先進抗體(2020年):Frost Radar Frost Radar: Advanced Antibodies, 2020
出版日期: 2020年12月15日內容資訊: 英文 33 Pages
簡介

由於抗體為基礎的治療方法的進步,雙特異性抗體(bsAbs),Hemlibra的法規當局對Amgen的blinatumomab (Blincyto®) 及Chugai的A型血友病的認證後,過去數年氣勢增加。雙特異性抗體是非常有前途等級的治療方法,50年多前概念化,不過,蛋白質工程,免疫抗原性,穩定性,及製造相關的課題使其商品化衰弱。

本報告以先進抗體市場上前臨床/1期開發的候補企業除外的短期商業性實現的企業為焦點,提供有創新性,短期成長可能性的企業(Tier1製藥/生物醫藥品企業除外)的簡介,策略性洞察能力,成長環境等資訊。

目錄

策略性命令及成長環境

  • 策略性命令
  • 成長環境
  • 成長環境

FrostRadar先進抗體

調查對象企業

  • Affimed Therapeutics GmbH
  • AlphaMab Oncology
  • Chugai
  • EpimAb Biotherapeutics
  • Genmab
  • Macrogenics Inc.
  • Merus NV
  • Xencor
  • Zymeworks

策略性洞察能力

接下來的步驟:FrostRadar的有效利用

FrostRadar分析

  • FrostRadar:未來的成長性基準
  • 免責聲明
目錄
Product Code: D9C2

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

With advances in antibody-based therapies, bispecific antibodies (bsAbs) have gained momentum in the last few years after the regulatory approvals of Amgen's blinatumomab (Blincyto®) and Chugai's Hemlibra for Hemophilia A. The key advantage of bsAbs lies in their ability to bind two different epitopes or antigens, thereby overcoming the limitations of monoclonal antibodies, which can only bind to a single epitope. Bispecific antibodies represent a highly promising class of therapeutics and were conceptualized more than 5 decades ago, but challenges associated with protein engineering, immunogenicity, stability, and manufacturing have dampened their commercialization.

Bispecific antibodies (bispecifics) are considered as the next gen antibody therapeutics, which could be used in cancer treatment for better cytotoxic effects, and also hold promise for certain therapeutic applications ,which are complex and refractory to other modalities, such as immune cell retargeting, site-specific targeting, and CNS targeting. With several advanced antibody engineering technologies in place- bispecific antibodies are demonstrating a high potential to transform cancer immunotherapy landscape, and also bring about a significant change in the treatment of infectious diseases and autoimmune diseases.

This Frost Radar™ profiles companies (excluding Tier 1 pharma/biopharma companies), which are highly innovative and primed for growth in the near term. It has excluded companies, which have candidates in pre-clinical/phase 1 development, and is focused on companies, which would have a near term commercial realization.

Table of Contents

Strategic Imperative and Growth Environment

  • Strategic Imperative
  • Growth Environment
  • Growth Environment

Frost Radar™Advanced Antibodies

  • Frost Radar™: Advanced Antibodies
  • Frost Radar™
  • Frost Radar™

Companies to Action:

  • Affimed Therapeutics GmbH
  • AlphaMab Oncology
  • Chugai
  • EpimAb Biotherapeutics
  • Genmab
  • Macrogenics Inc.
  • Merus NV
  • Xencor
  • Zymeworks

Strategic Insights

  • Strategic Insights

Next Steps: Leveraging the Frost Radar™ to Empower Key Stakeholders

  • Significance of Being on the Frost Radar™
  • Frost Radar™ Empowers the CEO's Growth Team
  • Frost Radar™ Empowers Investors
  • Frost Radar™ Empowers Customers
  • Frost Radar™ Empowers the Board of Directors

Frost Radar™Analytics

  • Frost Radar™: Benchmarking Future Growth Potential
  • Frost Radar™: Benchmarking Future Growth Potential
  • Legal Disclaimer